menu

CME: Decision Point IBD: Debating the Factors That Influence Patient-Centric Treatment

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Decision Point IBD: Debating the Factors That Influence Patient-Centric Treatment

close
0.25 credits
15 Minutes
Decision Point IBD: Debating the Factors That Influence Patient-Centric Treatment
Restart
Resume
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Comments
  • Overview

    Treat-to-target goals are part of the ever-changing, patient-centric environment associated with the management of inflammatory bowel disease (IBD). So how can you keep those goals in mind when treating your patients with IBD?  This Clinical Case Countdown challenges Dr. Uma Mahadevan and Dr. Fernando Velayos to address a range of clinical scenarios before the clock runs out. Can they “Beat the Buzzer?”

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Uma Mahadevan, MD
    Professor of Medicine
    University of California, San Francisco
    San Francisco, CA 
    Consulting Fees: AbbVie, Genentech, Gilead, Lilly, Janssen, Takeda
    Research: Celgene, Pfizer

    Fernando S. Velayos, MD, MPH
    Director, Regional Program in Inflammatory Bowel Disease
    Kaiser Permanente Northern California
    Professor of Medicine, University of California, San Francisco
    San Francisco, CA
    Research: Gilead, Tigenix 

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Stephen Chavez has nothing to disclose
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Jessica McGrory has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Correlate evolving treatment approaches with treat-to-target strategies according to specific patient-related factors 
  • Target Audience

    This activity is designed to meet the educational needs of Gastroenterologists, GI NP/PAs and GI Nurses.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by an independent educational grant from AbbVie, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited


    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Treat-to-target goals are part of the ever-changing, patient-centric environment associated with the management of inflammatory bowel disease (IBD). So how can you keep those goals in mind when treating your patients with IBD?  This Clinical Case Countdown challenges Dr. Uma Mahadevan and Dr. Fernando Velayos to address a range of clinical scenarios before the clock runs out. Can they “Beat the Buzzer?”

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Uma Mahadevan, MD
    Professor of Medicine
    University of California, San Francisco
    San Francisco, CA 
    Consulting Fees: AbbVie, Genentech, Gilead, Lilly, Janssen, Takeda
    Research: Celgene, Pfizer

    Fernando S. Velayos, MD, MPH
    Director, Regional Program in Inflammatory Bowel Disease
    Kaiser Permanente Northern California
    Professor of Medicine, University of California, San Francisco
    San Francisco, CA
    Research: Gilead, Tigenix 

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Stephen Chavez has nothing to disclose
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Jessica McGrory has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Correlate evolving treatment approaches with treat-to-target strategies according to specific patient-related factors 
  • Target Audience

    This activity is designed to meet the educational needs of Gastroenterologists, GI NP/PAs and GI Nurses.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by an independent educational grant from AbbVie, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited


    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 4/7/20